Search for a trial

An open-label, phase Ib, dose-escalation trial on the safety, tolerability, pharmacokinetics, immunogenicity, biological effects and antitumor activity of EMD 521873 in combination with local irradiation (20 Gy) of primary tumors or metastases in subjects with non-small cell lung cancer stage IIIb with malignant pleural effusion or stage IV with disease control (partial response or stable disease) after application of 4 cycles of platinum-based, first-line chemotherapy.

The primary objective will be to assess the safety and tolerability of this combination and to determine whether the MTD ofEMD 521873 is reached up to a dose of 0.45 mg/kg. Secondary objectives will be the evaluation of the PK, immunogenicity,…

A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low risk for recurrence: NVALT-8A

The primary aim of the study is to investigate whether it is possible to select patients by PET in a good prognosis group (i.e. low SUV) who will not benefit from adjuvant chemotherapy.

Concurrent ONce-daily VErsus twice-daily
RadioTherapy: A 2-arm randomised controlled trial of
concurrent chemo-radiotherapy comparing twice-daily
and once-daily radiotherapy schedules in patients with
limited stage small cell lung cancer (SCLC) and good
performance status.

To compare the primary endpoint (overall survival) between the two arms of the studySecondary endpoints are:Local progression-free survivalMetastases-free survivalCTCAE v3.0 toxicityChemotherapy dose intensityRadiotherapy dose intensity

Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a "sensitive" relapse

To assess the therapeutic activity of SU11248 in patients with exptensive disease small cell lung cancer who are either chemonaive or have a sensitive relapse

Lymphoscintigraphy in head and neck patients treated with primary radiotherapy

To analyze the change in lymphatic mapping in HNSCC patients treated by primary radiation therapy on the primary tumor and neck.

A phase II study of carboplatin -paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy.

Primary objective: Efficacy of erlotinib plus bevacizumab subsequent to the combination of carboplatin, paclitaxel and bevacizumab as determined by the maximum achieved disease control rate (DCR, complete response, partial response, or stable…

A PHASE 0 SINGLE MICRODOSE STUDY TO EVALUATE THE PHARMACOKINETICS/-DYNAMICS AND SPECIFIC TUMORTARGETING OF 124-I-F16SIP IN HEAD AND NECK CANCER PATIENTS

To evaluate the tumor targeting performance of the human radiolabeled antibody 124I-F16SIP.To investigate pharmacokinetics/-dynamics of 124I-F16SIP, and to assess its uptake in tumor and normal tissues as obtained from the surgical specimen.

A parallel phase II study of Tarceva®(Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in current and former smokers

To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.

Monitoring the microcirculation of patients with advanced lungcancer treated with bevacizumab and chemotherapy using optical spectroscopy.

2.1 Primary objectives Primary objective is scientific research to study the additional effect of bevacizumab on hypoxia related parameters. 2.2 Secondary objectives a) To compare the efficacy of bevacizumab with pre-treatment obtained values of…

Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement.

Main:the objective of this randomized trial would be to study disease free survival (DFS) in a population with completely resected NSCLC with homolateral lymph node mediastinal involvement histological or cytological proven. Who will randomly be…

Designing and testing new intervention therapies for lung cancer and mesothelioma

The aim of this study is to design and test new intervention therapies on tumorcells or tumorsamples on there sensitivity for several new drugs. Last few years there are a lot of new drugs available for cancer and have to be tested on there…

A randomized trial comparing longstanding indwelling pleural catheters with pleurodesis as a frontline treatment for malignant pleural effusion.

To compare the palliative efficacy of talc pleurodesis with the indwelling catheter

A 2-step phase I study evaluating the safety of (neo-)adjuvant cisplatin-pemetrexed and stereotactic radiotherapy for patients with stage IB non-small-cell lung cancer

Primary goal is studying the safety and feasibility of administering chemotherapy (cisplatin and pemetrexed) after of before treatment with stereotactic radiotherapy by observing and recording toxicity during and after the study.

Imaging of [11C]erlotinib pharmacokinetics in non small cell lung cancer patients; an in vivo study with positron emission tomography

Primary Objective: To study the tumour pharmacokinetics of [11C]erlotinib in NSCLC patients in vivo and relating uptake with EGFR mutations, obtained from tumour biopsies. Secondary Objective(s): 1. to define the test-retest reproducibility of [11C]…

Adherence and patients' experiences with the use of erlotinib in NSCLC treatment: The influence on plasma concentration and the exploration of factors affecting the use in daily practice

Primary Objective: To study the relationship between adherence and the plasma concentration of erlotinib and to study the relationship between side effects and adherence to erlotinib in patients with NSCLC.Secondary Objective: The study is partly of…

*Prospective cohort study on the prevalence of obstructive sleep apnea in patients with head and neck cancer treated with either radiotherapy, chemoradiation or surgery*

The primary objective is to evaluate the percentage of the study population who have OSAS before and after treatment and the severity of it. A second objective is to correlate the prevalence of OSAS with different tumour sites and stages, as well as…

Validation of a Prognostic Profile of Non Small Cell Lung Cancer in biopsies, PulmoPrint

Comparison of micro arrays from biopsy material and surgical specimen for the 72 gene- prognostic profile of non-small cell lung cancer.

Study to investigate the effects of bevacizumab on [11C]docetaxel kinetics in lung tumours using PET-CT

1. To study the effects of bevacizumab on [11C]docetaxel uptake by lung tumours.2. To study the early effects of bevacizumab on tumour blood flow.3. To study the relation between [11C]docetaxel uptake and blood flow in tumours after administration…

Prediction of radiation induced lung damage based on dose distribution and tumour location. A pilot study.

To investigate the newly developed method to study lung density changes using CT-scan, in a small patient population. The relationship between radiation induced lung density changes and dose distribution/tumor location will be investigated.

[18F]-Fluorodeoxyglucose Positron Emission Tomography in Lung Tumour Assessment, Research into Characteristics

To find correlations between tumour dimensions obtained by thresholds of uptake (SUV), metabolism (MRglu) or modelled thresholds (RTL) as measured during dynamic acquisition and anatomic (CT) and pathological data. Secondary objectives are the…